<DOC>
	<DOCNO>NCT00585078</DOCNO>
	<brief_summary>There limited treatment option available patient advance pancreatic ductal adenocarcinoma ( PDAC ) . The purpose study determine effectiveness safety drug capecitabine oxaliplatin patient diagnose advanced metastatic PDAC treat first second line .</brief_summary>
	<brief_title>Capecitabine Oxaliplatin Patients With Advanced Metastatic Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine response rate capecitabine oxaliplatin patient locally advance metastatic pancreatic adenocarcinoma Secondary - To determine safety - To determine overall survival - To determine time progression</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>18 year age old At one prior chemotherapy regimen unresectable metastatic disease . Any adjuvant chemotherapy must complete 12 month prior begin protocol therapy Histologically cytologically confirm adenocarcinoma pancreas At least one measurable lesion accord RECIST criterion irradiate Adequate laboratory parameter outline protocol Anticoagulation coumadin permit , PT/INR must monitor closely , give drugdrug interaction coumadin capecitabine Negative serum pregnancy test within 14 day prior registration Pregnant lactating woman Life expectancy &lt; 3 month Serious , uncontrolled , concurrent infection ( ) Any prior oxaliplatin fluoropyrimidine therapy More one prior chemotherapy regimen unresectable metastatic disease Prior unanticipated severe reaction fluoropyrimidine therapy , know sensitivity 5fluorouracil platinum compound Any active second malignancy Clinically significant cardiac disease myocardial infarction within last 12 month Evidence CNS metastases history uncontrolled seizure , central nervous system disorder psychiatric disability Other serious uncontrolled medical condition Major surgery within 4 week start study treatment , without complete recovery Lack physical integrity upper gastrointestinal tract malabsorption syndrome Known , exist uncontrolled coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>capecitabine</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>